Lataa...
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate t...
Tallennettuna:
| Julkaisussa: | ESC Heart Fail |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7754994/ https://ncbi.nlm.nih.gov/pubmed/32915523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12891 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|